Literature DB >> 22566565

IL-17 and TNF-α sustain neutrophil recruitment during inflammation through synergistic effects on endothelial activation.

Gabriel K Griffin1, Gail Newton, Margarite L Tarrio, De-xiu Bu, Elena Maganto-Garcia, Veronica Azcutia, Pilar Alcaide, Nir Grabie, Francis W Luscinskas, Kevin J Croce, Andrew H Lichtman.   

Abstract

IL-17A (IL-17) is the signature cytokine produced by Th17 cells and has been implicated in host defense against infection and the pathophysiology of autoimmunity and cardiovascular disease. Little is known, however, about the influence of IL-17 on endothelial activation and leukocyte influx to sites of inflammation. We hypothesized that IL-17 would induce a distinct pattern of endothelial activation and leukocyte recruitment when compared with the Th1 cytokine IFN-γ. We found that IL-17 alone had minimal activating effects on cultured endothelium, whereas the combination of TNF-α and IL-17 produced a synergistic increase in the expression of both P-selectin and E-selectin. Using intravital microscopy of the mouse cremaster muscle, we found that TNF-α and IL-17 also led to a synergistic increase in E-selectin-dependent leukocyte rolling on microvascular endothelium in vivo. In addition, TNF-α and IL-17 enhanced endothelial expression of the neutrophilic chemokines CXCL1, CXCL2, and CXCL5 and led to a functional increase in leukocyte transmigration in vivo and CXCR2-dependent neutrophil but not T cell transmigration in a parallel-plate flow chamber system. By contrast, endothelial activation with TNF-α and IFN-γ preferentially induced the expression of the integrin ligands ICAM-1 and VCAM-1, as well as the T cell chemokines CXCL9, CXCL10, and CCL5. These effects were further associated with a functional increase in T cell but not neutrophil transmigration under laminar shear flow. Overall, these data show that IL-17 and TNF-α act in a synergistic manner to induce a distinct pattern of endothelial activation that sustains and enhances neutrophil influx to sites of inflammation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22566565      PMCID: PMC3370121          DOI: 10.4049/jimmunol.1200385

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  70 in total

1.  Treatment with IL-17 prolongs the half-life of chemokine CXCL1 mRNA via the adaptor TRAF5 and the splicing-regulatory factor SF2 (ASF).

Authors:  Dongxu Sun; Michael Novotny; Katarzyna Bulek; Caini Liu; Xiaoxia Li; Thomas Hamilton
Journal:  Nat Immunol       Date:  2011-08-07       Impact factor: 25.606

2.  IL-17A acts via p38 MAPK to increase stability of TNF-alpha-induced IL-8 mRNA in human ASM.

Authors:  Sheridan Henness; Eveline van Thoor; Qi Ge; Carol L Armour; J Margaret Hughes; Alaina J Ammit
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2006-06       Impact factor: 5.464

3.  Interleukin-17 accelerates allograft rejection by suppressing regulatory T cell expansion.

Authors:  Satoshi Itoh; Naoyuki Kimura; Robert C Axtell; Jeffrey B Velotta; Yongquan Gong; Xi Wang; Naoki Kajiwara; Aya Nambu; Eri Shimura; Hideo Adachi; Yoichiro Iwakura; Hirohisa Saito; Ko Okumura; Katsuko Sudo; Lawrence Steinman; Robert C Robbins; Susumu Nakae; Michael P Fischbein
Journal:  Circulation       Date:  2011-09-13       Impact factor: 29.690

4.  IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis.

Authors:  Yutaka Komiyama; Susumu Nakae; Taizo Matsuki; Aya Nambu; Harumichi Ishigame; Shigeru Kakuta; Katsuko Sudo; Yoichiro Iwakura
Journal:  J Immunol       Date:  2006-07-01       Impact factor: 5.422

5.  IL-17 production is dominated by gammadelta T cells rather than CD4 T cells during Mycobacterium tuberculosis infection.

Authors:  Euan Lockhart; Angela M Green; JoAnne L Flynn
Journal:  J Immunol       Date:  2006-10-01       Impact factor: 5.422

6.  Role of interleukin 17 in inflammation, atherosclerosis, and vascular function in apolipoprotein e-deficient mice.

Authors:  Meena S Madhur; Samuel A Funt; Li Li; Antony Vinh; Wei Chen; Heinrich E Lob; Yoichiro Iwakura; Yelena Blinder; Ayaz Rahman; Arshed A Quyyumi; David G Harrison
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-04-07       Impact factor: 8.311

Review 7.  Structure and signalling in the IL-17 receptor family.

Authors:  Sarah L Gaffen
Journal:  Nat Rev Immunol       Date:  2009-07-03       Impact factor: 53.106

8.  Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity.

Authors:  Caroline E Sutton; Stephen J Lalor; Cheryl M Sweeney; Corinna F Brereton; Ed C Lavelle; Kingston H G Mills
Journal:  Immunity       Date:  2009-08-13       Impact factor: 31.745

9.  Interleukin-17-producing gammadelta T cells selectively expand in response to pathogen products and environmental signals.

Authors:  Bruno Martin; Keiji Hirota; Daniel J Cua; Brigitta Stockinger; Marc Veldhoen
Journal:  Immunity       Date:  2009-08-13       Impact factor: 31.745

10.  Myeloperoxidase (MPO) and interleukin-17 (IL-17) plasma levels are increased in patients with acute coronary syndromes.

Authors:  J Liang; Z Zheng; M Wang; L Han; Z Zheng; J Peng; Z Liu; Y Wei
Journal:  J Int Med Res       Date:  2009 May-Jun       Impact factor: 1.671

View more
  137 in total

Review 1.  Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release.

Authors:  Nazila Kamaly; Basit Yameen; Jun Wu; Omid C Farokhzad
Journal:  Chem Rev       Date:  2016-02-08       Impact factor: 60.622

2.  Croton antisyphiliticus Mart. attenuates the inflammatory response to carrageenan-induced pleurisy in mice.

Authors:  Gustavo Oliveira Dos Reis; Geison Vicente; Francieli Kanumfre de Carvalho; Melina Heller; Gustavo Amadeu Micke; Moacir Geraldo Pizzolatti; Tânia Silvia Fröde
Journal:  Inflammopharmacology       Date:  2013-08-29       Impact factor: 4.473

Review 3.  Reactive oxygen species in inflammation and tissue injury.

Authors:  Manish Mittal; Mohammad Rizwan Siddiqui; Khiem Tran; Sekhar P Reddy; Asrar B Malik
Journal:  Antioxid Redox Signal       Date:  2013-10-22       Impact factor: 8.401

4.  Elevated CXCL1 expression in gp130-deficient endothelial cells impairs neutrophil migration in mice.

Authors:  Longbiao Yao; Tadayuki Yago; Bojing Shao; Zhenghui Liu; Robert Silasi-Mansat; Hendra Setiadi; Florea Lupu; Rodger P McEver
Journal:  Blood       Date:  2013-09-30       Impact factor: 22.113

Review 5.  Effector mechanisms of rejection.

Authors:  Aurélie Moreau; Emilie Varey; Ignacio Anegon; Maria-Cristina Cuturi
Journal:  Cold Spring Harb Perspect Med       Date:  2013-11-01       Impact factor: 6.915

6.  The tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20) imposes a brake on antitumor activity of CD8 T cells.

Authors:  Marilyn Giordano; Romain Roncagalli; Pierre Bourdely; Lionel Chasson; Michel Buferne; Sho Yamasaki; Rudi Beyaert; Geert van Loo; Nathalie Auphan-Anezin; Anne-Marie Schmitt-Verhulst; Grégory Verdeil
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-14       Impact factor: 11.205

7.  Evaluation of neuroprotective effects of insulin on immuno-inflammatory and systemic disorders induced by kaliotoxin, a Kv1.3 channel blocker.

Authors:  Zahida Taibi-Djennah; Marie-France Martin-Eauclaire; Fatima Laraba-Djebari
Journal:  Inflamm Res       Date:  2018-08-06       Impact factor: 4.575

Review 8.  The current state of the art for biological therapies and new small molecules in inflammatory bowel disease.

Authors:  Sudarshan Paramsothy; Adam K Rosenstein; Saurabh Mehandru; Jean-Frederic Colombel
Journal:  Mucosal Immunol       Date:  2018-06-15       Impact factor: 7.313

Review 9.  The complexity of neutrophils in health and disease: Focus on cancer.

Authors:  Silvia Carnevale; Somayehsadat Ghasemi; Anna Rigatelli; Sebastien Jaillon
Journal:  Semin Immunol       Date:  2020-09-18       Impact factor: 11.130

Review 10.  Basic biology and role of interleukin-17 in immunity and inflammation.

Authors:  Camille Zenobia; George Hajishengallis
Journal:  Periodontol 2000       Date:  2015-10       Impact factor: 7.589

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.